Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand (vol 28, pg 590, 2021)

被引：0
|
作者：
Yu, Junhui
Yang, Kui
Zheng, Jianbao
Zhao, Wei
Sun, Xuejun
机构：
[1] First Affiliated Hospital of Xi’an Jiaotong University,Department of General Surgery
来源：
CANCER GENE THERAPY | 2022年 / 29卷 / 06期
关键词：
D O I：
10.1038/s41417-021-00368-8
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：871 / 872
页数：2
相关论文
共 15 条
  • [1] Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand
    Junhui Yu
    Kui Yang
    Jianbao Zheng
    Wei Zhao
    Xuejun Sun
    Cancer Gene Therapy, 2021, 28 : 590 - 601
  • [2] Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand
    Yu, Junhui
    Yang, Kui
    Zheng, Jianbao
    Zhao, Wei
    Sun, Xuejun
    CANCER GENE THERAPY, 2021, 28 (06) : 590 - 601
  • [3] Correction: Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand
    Junhui Yu
    Kui Yang
    Jianbao Zheng
    Wei Zhao
    Xuejun Sun
    Cancer Gene Therapy, 2022, 29 : 871 - 872
  • [4] Synergistic growth inhibition of human hepatocellular carcinoma cells by acyclic retinoid and GW4064, a farnesoid X receptor ligand
    Ohno, Tomohiko
    Shimizu, Masahito
    Kubota, Masaya
    Sakai, Hiroyasu
    Moriwaki, Hisataka
    CANCER RESEARCH, 2012, 72
  • [5] Synergistic growth inhibition of human hepatocellular carcinoma cells by acyclic retinoid and GW4064, a farnesoid X receptor ligand
    Ohno, Tomohiko
    Shirakami, Yohei
    Shimizu, Masahito
    Kubota, Masaya
    Sakai, Hiroyasu
    Yasuda, Yoichi
    Kochi, Takahiro
    Tsurumi, Hisashi
    Moriwaki, Hisataka
    CANCER LETTERS, 2012, 323 (02) : 215 - 222
  • [6] Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatowhepatitis FLINT): a multicentre, randomised, placebo-controlled trial (vol 385, pg 956, 2015)
    Neuschwander-Tetri, B. A.
    Loomba, R.
    Sanyal, A. J.
    LANCET, 2016, 387 (10028) : 1618 - 1618
  • [7] Synergistic Effect Of A Retinoid X Receptor-Selective Ligand Bexarotene And Docetaxel In Prostate Cancer (vol 12, pg 7877, 2019)
    Shen, Danyang
    Wang, Huan
    Zheng, Qiming
    Cheng, Sheng
    Xu, Liwei
    Wang, Mingchao
    Li, Gonghui
    Xia, Liqun
    ONCOTARGETS AND THERAPY, 2019, 12 : 8807 - 8807
  • [8] Inactivation of Adenomatous Polyposis Coli Reduces Bile Acid/Farnesoid X Receptor Expression through Fxr gene CpG Methylation in Mouse Colon Tumors and Human Colon Cancer Cells
    Selmin, Ornella I.
    Fang, Changming
    Lyon, Adam M.
    Doetschman, Tom C.
    Thompson, Patricia A.
    Martinez, Jesse D.
    Smith, Jeffrey W.
    Lance, Peter M.
    Romagnolo, Donato F.
    JOURNAL OF NUTRITION, 2016, 146 (02) : 236 - 242
  • [9] Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells (vol 37, pg 405, 2015)
    Sun, Rong
    Liu, Yang
    Li, Shi-Yong
    Shen, Song
    Du, Xiao-Jiao
    Xu, Cong-Fei
    Cao, Zhi-Ting
    Bao, Yan
    Zhu, Yan-Hua
    Li, Ya-Ping
    Yang, Xian-Zhu
    Wang, Jun
    BIOMATERIALS, 2020, 263
  • [10] Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition (vol 23, pg 1002, 2021)
    Mani, Chinnadurai
    Tripathi, Kaushlendra
    Chaudhart, Sandeep
    Somasagara, Ranganatha R.
    Rocconi, Rodney P.
    Crasto, Chiquito
    Athar, Mohammad
    Palle, Komaraiah
    NEOPLASIA, 2024, 50
12